Literature DB >> 25824151

Using Elecsys® HIV Combi PT assay to identify acute and early HIV infection in a teaching hospital of southwest China.

Siyuan Zhu1, Dongdong Li1, Jingna An1, Qixia Chen1, Qianqian Liu1, Chuanmin Tao2.   

Abstract

This study is the first attempt to evaluate the use of the Elecsys® HIV combi PT assay in identifying acute and early HIV infection in southwest China. We also analyzed the extent of cutoff ratios overlap between false-positive and true-positive results to aid the identification of HIV infection, using samples from the West China Hospital in Chengdu, Sichuan Province from April 2012 to December 2013. Reactive results from a screening test were retested and all repeatedly reactive samples - if available - were confirmed with Western blot, HIV-1 p24 antigen, or HIV-1 RNA. Of 241,840 samples screened, the Elecsys® HIV combi PT assay identified 54 patients with acute and early HIV infection; 99.8% cases with cutoff index ratios ≥50 were proved to be true-positive HIV infection and 95.6% cases with cutoff index ratios <15 were falsely positive. In conclusion, the Elecsys® HIV combi PT assay can identify acute and early HIV infection, including those who might have been missed by third-generation HIV screening assays and Western blot. However, cutoff index ratios <15 are not always false-reactive results; a definitive result cannot be attained without further confirmation. In resource-poor regions where a HIV-1 nucleic acid test may be unaffordable, detection of HIV-1 p24 antigen can be an alternative strategy to diagnose HIV infection in individuals with a negative or indeterminate Western blot.
© The Author(s) 2015.

Entities:  

Keywords:  AIDS; Elecsys® HIV combi PT assay; HIV; acute and early HIV infection; diagnosis; testing

Mesh:

Substances:

Year:  2015        PMID: 25824151     DOI: 10.1177/0956462415579589

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  1 in total

1.  HIV false positive screening serology due to sample contamination reduced by a dedicated sample and platform in a high prevalence environment.

Authors:  Michael A Linström; Wolfgang Preiser; Nokwazi N Nkosi; Helena W Vreede; Stephen N J Korsman; Annalise E Zemlin; Gert U van Zyl
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.